 Century Therapeutics Inc NASDAQ: IPSC and Bristol Myers Squibb Co NYSE: BMY have announced a research collaboration and license agreement for up to four induced pluripotent stem cell iPSC programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform. 